Physician profile
David Thomas Bailey
NPI 1144742453
$8,152.17
in general payments reported to CMS, 2019-2025
30 companies · $1,043 in 2025
The $1,043 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $830 · 2022: $1,458 · 2023: $2,220 · 2024: $2,600 · 2025: $1,043.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,806 · Education: $57.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,806.11 |
| Education | $57.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,862.91 | 2021-2025 | |
| Janssen Biotech, INC. | $1,275.47 | 2021-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $802.13 | 2021-2025 | Entyvio, Eohilia |
| Pfizer INC. | $624.09 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $520.72 | 2021-2025 | Xifaxan, Trulance |
| Ardelyx, INC. | $318.86 | 2022-2025 | Ibsrela |
| Celgene Corporation | $303.13 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $291.90 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $282.33 | 2022-2025 | Dupixent |
| Qol Medical, LLC | $268.05 | 2021-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $229.46 | 2022-2025 | |
| Gilead Sciences, INC. | $156.45 | 2021-2024 | |
| Lilly USA, LLC | $155.14 | 2024-2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $143.69 | 2021-2024 | Linzess |
| Redhill Biopharma INC. | $139.06 | 2021-2023 | Aemcolo, Talicia, Movantik |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $133.49 | 2022 | |
| Celltrion USA INC. | $119.80 | 2024-2025 | Zymfentra, Vegzelma |
| Braintree Laboratories, INC. | $100.07 | 2022-2024 | Sutab, Suflave |
| Amgen INC. | $61.53 | 2021-2025 | |
| Organon LLC | $57.00 | 2023-2024 | Renflexis, Hadlima |
| Boston Scientific Corporation | $52.71 | 2021-2023 | |
| Fresenius Kabi USA, LLC | $50.93 | 2023-2024 | Idacio |
| Phathom Pharmaceuticals, INC. | $45.97 | 2024 | Voquezna |
| Intra-Sana Laboratories | $38.78 | 2022 | |
| Janssen Scientific Affairs, LLC | $23.46 | 2024 | Stelara |
| Ipsen Biopharmaceuticals, INC | $21.98 | 2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $20.94 | 2022 | |
| Sanofi-Aventis U.S. LLC | $19.51 | 2021 | |
| Nestle Healthcare Nutrition INC. | $17.07 | 2022 | |
| Aimmune Therapeutics, INC. | $15.54 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.